Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

Drug: paclitaxel 80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle

Drug: topotecan 4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle

Drug: liposomal doxorubicin 40mg/m2 iv every 4 weeks

Drug: bevacizumab \[Avastin\] 10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks